Geneos Therapeutics, Inc.

Iambic Therapeutics is the latest biopharmaceutical company to raise a venture capital mega-round in support of an artificial intelligence-powered drug discovery platform and emerging clinical-stage

Neuron23 Inc. aims to take two small molecule drug candidates for neurological diseases into the clinic during the next two years, with $100m from a series C venture capital round that the company an

The Biotechnology Innovation Organization (BIO) released new data on financings for emerging therapeutic companies that shows record levels of venture capital investment – not just in the US, but glob

Series E Brings $18m To 3-V Biosciences 3-V Biosciences Inc. , which is developing drugs for cancer and nonalcoholic steatohepatitis (NASH), raised $18m through its Series E round. New investor and p